18 November 2026 in Research Square
Background: To describe the real-world safety, steroid-sparing effect, treatment duration, infusion interval, and operational features of a medical ophthalmology-led biologic service managing non-infectious uveitis(NIU) patients with infliximab(IFX). Methods: Retrospective cohort review of patients receiving IFX for NIU at a tertiary NHS centre from March 2016 to March 2026. Primary outcomes were adverse events(AEs), serious adverse events(SAEs) and discontinuations; secondary outcomes were oral corticosteroid requirement and visual acuity. Results: 44 patients contributed 1208 months of IFX exposure (100.7 patient-years), with a median of 21.5 months(IQR 9.5–32.0). 37/44 (84%) had previously received adalimumab. AEs were reported by 20/44 (45%), including infections in 10/44 (23%) and rash in 9/44 (20%). SAEs occurred in 2/44 (5%): incident heart failure and anaphylaxis, each in 1/44 (2%). AEs led to discontinuation in 8/44 (18%). By 12 months, 10/44 (23%) had stopped IFX, most commonly due to ineffectiveness. Worse eye visual acuity changed by <15 ETDRS letters from baseline in 29/33 (88%), improved by ≥15 letters in 3/33 (9%), and worsened by ≥15 in 1/33 (3%). Among those using prednisolone at baseline, the median daily dose fell from 15 mg to 5.5 mg by month 12; at latest review (median 27 months) the median was 4.0 mg/day, with 18/21 (86%) taking ≤5 mg/day and 5/21 (24%) steroid-free. Conclusions: IFX was generally well tolerated and was associated with lower corticosteroid requirements in NIU. A medical ophthalmology-led biologic infusion service is feasible and safe but close collaboration with other medical specialties is critical for safe governance and delivery.